The unrestrained growth of tumor cells is generally attributed to mutations in essential growth control genes, but tumor cells are also affected by, or even addicted to, signals from the microenvironment. As therapeutic targets, these extrinsic signals may be equally significant as mutated oncogenes. In multiple myeloma (MM), a plasma cell malignancy, most tumors display hallmarks of active Wnt signaling but lack activating Wnt-pathway mutations, suggesting activation by autocrine Wnt ligands and/or paracrine Wnts emanating from the bone marrow (BM) niche. Here, we report a pivotal role for the R-spondin/leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) axis in driving aberrant Wnt/ β-catenin signaling in MM. We show that LGR4 is expressed by MM plasma cells, but not by normal plasma cells or B cells. This aberrant LGR4 expression is driven by IL-6/STAT3 signaling and allows MM cells to hijack R-spondins produced by (pre)osteoblasts in the BM niche, resulting in Wnt (co)receptor stabilization and a dramatically increased sensitivity to auto-and paracrine Wnts. Our study identifies aberrant R-spondin/LGR4 signaling with consequent deregulation of Wnt (co)receptor turnover as a driver of oncogenic Wnt/ β-catenin signaling in MM cells. These results advocate targeting of the LGR4/R-spondin interaction as a therapeutic strategy in MM.
multiple myeloma | Wnt signaling | LGR4 | R-spondins | osteoblast M ultiple myeloma (MM) in most patients is an incurable hematologic malignancy characterized by the accumulation of clonal plasma cells in the bone marrow (BM). Despite the wide variety of underlying structural and numerical genomic abnormalities (1) (2) (3) , virtually all MMs are highly dependent on a protective BM microenvironment, or "niche," for growth and survival (4) . Understanding the complex reciprocal interaction between MM cells and the BM microenvironment is critical for the development of new targeted therapies.
In MM, aberrant activation of the canonical Wnt pathway drives proliferation and is associated with disease progression, dissemination, and drug resistance (5) (6) (7) (8) (9) . Because MMs with hallmarks of active Wnt signaling do not harbor mutations that typically underlie constitutive Wnt pathway activation, this oncogenic Wnt pathway activity was proposed to involve autocrine and/or paracrine Wnt ligands (6, 8, 10) . Wnts are lipid-modified glycoproteins that function as typical niche factors because they are relatively unstable and insoluble due to their hydrophobic nature, which constrains long-range signaling (11) . Binding of a Wnt ligand to its receptor Frizzled (Fzd) initiates a signaling cascade that ultimately results in stabilization and nuclear translocation of the Wnt effector β-catenin. In cooperation with TCF/LEF family transcription factors this orchestrates a transcriptional program (12, 13) , comprising targets such as MYC and CCND1 (Cyclin D1) that play crucial roles in the pathogenesis of MM (14) (15) (16) . Aberrant Wnt signaling in cancer typically results from mutations in APC, β-catenin (CTNNB1), or AXIN that drive constitutive, ligand-independent pathway activation (10) . Interestingly, mutations in regulators of Wnt receptor turnover, causing hypersensitivity to Wnt ligands, have recently been described in a variety of tumors, identifying aberrant Wnt (co)receptor turnover as an alternative mechanism driving oncogenic Wnt signaling (17) (18) (19) . Turnover of Wnt (co)receptors is critically regulated by leucine-rich repeat-containing G protein-coupled receptor (LGR)-family receptors, which stabilize Wnt (co)receptors in response to their cognate ligand R-spondin. R-spondin/LGR signaling alleviates the inhibitory effect of two homologous membrane-bound E3 ubiquitin ligases, ZNRF3 and RNF43, which normally induce Wnt (co)receptor internalization (20-23). This strong positive regulatory effect on Wnt-signaling pathway activation designates the LGR/ R-spondin axis as potentially oncogenic, a notion that prompted us to explore its possible role in hematologic malignancies. Here, we identify aberrant LGR4/R-spondin signaling as a driver of oncogenic Wnt/β-catenin signaling in MM.
Results
LGR4 Is Aberrantly Expressed in MM. To gain insight into the expression of LGR4-6 in normal hematopoiesis and in hematologic malignancies, we initially analyzed publically available gene-expression
Significance
Multiple myeloma (MM) cells are highly dependent on signals provided by the bone marrow (BM) niche for growth and survival. Most MMs display hallmarks of active Wnt signaling, but lack activating Wnt-pathway mutations, suggesting activation by autocrine Wnt ligands and/or paracrine Wnts emanating from the BM niche. In this study we uncover a pivotal role for the leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4)/R-spondin axis in facilitating activation of Wnt signaling in MM.
LGR4 is expressed by most MMs, but not by healthy plasma cells, and is regulated by STAT3 signaling. LGR4 expression allows MMs to respond to (pre)osteoblast-derived R-spondins, resulting in stabilization of Wnt receptors and greatly enhanced sensitivity to autoand paracrine Wnt ligands. These results advocate targeting of proximal Wnt signaling in MM.
datasets. In normal bone marrow and lymphocyte subsets, as well as in most hematologic malignancies, LGR4-6 mRNA was virtually undetectable ( Fig. 1 and Fig. S1A ). Interestingly, however,
LGR4 expression was present in the majority of primary MMs (pMMs) (Fig. 1) at levels comparable to those in intestinal tissues (Fig. S1B) , in which the role of LGR/R-spondin signaling is well established (24) . No significant differences in LGR4 expression were observed between MMs from previously defined molecular subgroups ( Fig. S1C) (25) . Notably, no significant expression of LGR5 or LGR6 was detected in MM samples (Fig. S1D ). Quantitative PCR (qPCR) analysis confirmed LGR4 mRNA expression in most human multiple myeloma cell lines (HMCLs) and pMMs ( Fig. 2A) Fig. 2A) . No LGR5 and LGR6 mRNA was detected in pMM, HMCLs, and developing B cells by qPCR (Fig. S2A ). In agreement with the mRNA data, flow cytometric analysis using an LGR4-specific monoclonal antibody (mAb) (Fig. S2B ) revealed that LGR4 protein is expressed on the majority of pMMs and HMCLs (Fig. 2  B-D) but, importantly, not on human bone marrow-derived cells (hBMPCs) (Fig. 2B) or normal B-cell subsets (Fig. S2C). LGR5 protein expression was not detected in pMMs and HMCLs (Fig.  S2D ). These findings indicate that LGR4 expression in MM is a hallmark of malignant transformation and not a reflection of differentiation status or lineage commitment.
LGR4 Expression Is Transcriptionally Regulated by STAT3 Signaling.
STAT3 signaling is almost invariably activated in MM as a result of auto-or paracrine stimulation by and was recently shown to regulate LGR4 expression in osteosarcoma (29) . We therefore investigated whether STAT3 signaling also mediates aberrant LGR4 expression in MM. As expected, IL-6 treatment of the HMCL XG-1 and pMM cells induced phosphorylation of the tyrosine 705 residue of STAT3, indicating pathway activation ( Fig. S3 A and B) . Interestingly, IL-6 treatment of HMCLs and pMM cells and ectopic expression of a constitutively active (CA) STAT3 mutant in XG-1 induced robust LGR4 mRNA and protein expression ( 
R-spondins Potentiate Wnt Signaling in MM in a LGR4-Dependent
Manner. Functionally, R-spondin binding to LGR4 facilitates Wnt pathway activation by stabilization of Wnt (co)receptors, thereby increasing the sensitivity to Wnt ligands without activating Wnt signaling itself (20, 21). To establish whether the LGR4/R-spondin axis is instrumental in regulating Wnt signaling in MM cells, we initially assessed phosphorylation of the serine 1490 residue of lowdensity lipoprotein receptor-related protein 6 (LRP6) (Fig. S4A) , which sequesters Axin to the plasma membrane (30) , and the consequent stabilization and nuclear localization of β-catenin (Fig.  4A ). As expected, stimulation with Wnt3a alone induced LRP6 phosphorylation and nuclear translocation of β-catenin in all MM cell lines tested ( Fig. 4A and Fig. S4A ). However, stimulation with R-spondin alone did not result in Wnt pathway activation in the majority of cell lines ( Fig. 4A and Fig. S4A ), but modestly increased Wnt signaling in LME-1 (a 3.1-fold increase in pLRP6 and a 1. increase in nuclear β-catenin, Fig. 4A and Fig. S4A ), reflecting autocrine production of Wnts by the latter cells (see below). Simultaneous stimulation with R-spondin and Wnt ligands dramatically increased LRP6 phosphorylation and β-catenin stabilization/ translocation in all LGR4-positive HMCLs tested, but not in the LGR4-negative cell line L363 ( Fig. 4A and Fig. S4A ). To further study the role of LGR4 in amplification of Wnt signaling by R-spondin, we stably transduced HMCLs with a β-cateninsensitive fluorescent Wnt-reporter (TOP-GFP), which coexpresses a histone2B(H2B)/mCherry fusion protein as a transduction marker (Fig. S4B) , combined with either inducible shRNA-mediated silencing (Fig. S4C ) or CRISPR/Cas9-mediated gene disruption (Fig. 2D ) of LGR4. FACS-sorted TOP-GFP + MM cells displayed higher levels of nuclear β-catenin compared with TOP-GFP − cells, confirming specificity of the reporter (Fig. S4B ). In line with the observed increase in LRP6 phosphorylation and β-catenin stabilization, R-spondin robustly amplified Wnt reporter activity in the presence of Wnt ligands ( Fig. 4B and Fig. S4C ). Similar results were obtained upon transient transfection of the TOPflash luciferase reporter, which was activated up to 200-fold by simultaneous stimulation with Wnt3a and R-spondin (Fig. S5A) . Importantly, shRNA-mediated silencing of LGR4 and CRISPR/Cas9-mediated LGR4 gene disruption abolished the potentiating effect of R-spondins on Wnt-pathway activation ( Fig. 4B and Fig. S4C ), indicating a crucial role for LGR4.
In LME1 cells, Wnt receptor stabilization by R-spondin increased Wnt pathway activity in the absence of exogenous Wnts (Fig. 4 A and B and Fig. S4A ), suggesting autocrine Wnt production. Wnt secretion is dependent on palmitoylation by the porcupine enzyme, encoded by the PORC gene (31, 32) , and recently developed small-molecule porcupine inhibitors (IWP-2, LGK974) efficiently block this Wnt secretion (18, 33, 34) . Both porcupine inhibitors strongly inhibited the robust stabilization of β-catenin and Wnt reporter activation observed upon stimulation of LME-1 with R-spondin alone (Fig. 4C and Fig. S5B) , thus confirming the existence of an autocrine Wnt loop.
Taken together, these results demonstrate that R-spondins facilitate auto-and paracrine Wnt signaling in MM in an LGR4-dependent manner and suggest that Wnt (co)receptor levels are limiting in establishing high levels of Wnt-pathway activation in MM cells.
Inhibition of Proximal Wnt/β-Catenin Signaling Impairs Proliferation in a Subset of HMCLs. Downstream inhibition of Wnt/β-catenin signaling by a dominant negative form of TCF4 (dnTCF4) and shRNA-mediated silencing of β-catenin, BCL9-like peptides, or small-molecule Wnt inhibitors has been previously shown to impair MM proliferation and expansion (6, 7, 9, 35) . To confirm and extend these data, we expressed dnTCF4 in the HMCLs LME-1, RIES, and XG-1 from a bicistronic vector containing a fluorescent marker. Cells expressing dnTCF4 were rapidly outcompeted by cells that did not express dnTCF4 and incorporated less BrdU, confirming a role for Wnt signaling in MM cell expansion ( Fig. 5A and Fig. S6 A and B) . Interestingly, in LME-1 and RIES, inhibition of Wnt secretion by small-molecule porcupine inhibitors also impaired growth (Fig. 5B) , whereas XG-1 cells were unaffected (Fig. S6C) , suggesting that the LME-1 and RIES cell lines require autocrine Wnt secretion. Indeed, LME-1 cells displayed detectable levels of autocrine Wnt signaling (Fig.  4 and Fig. S5B ) whereas RIES cells were found to express extraordinarily high levels of LGR4 (Fig. S6D) . As shown in Fig.  5C , doxycycline-inducible, shRNA-mediated silencing of LGR4 (Fig. S6D ) significantly impaired expansion of LME-1 and RIES (Fig. 5C ), whereas silencing LGR4 in XG-1 had no apparent effect on cell growth (Fig. S6E) . Taken together, these data indicate functional involvement of (autocrine) Wnts and the R-spondin/ LGR4 axis in the growth of a subset of MMs.
R-Spondins Are Produced in the BM Niche by (Pre)osteoblasts. Wnts have been shown to regulate hematopoietic stem cell homeostasis and early B-cell development in a paracrine manner, and Wnt expression in the BM niche is well established (36, 37) . However, the source of R-spondins remains to be defined. Prime candidates are osteoblasts, which have recently been suggested to use autocrine R-spondin for their differentiation (38) and, moreover, are key constituents of the MM niche (39, 40) . We therefore analyzed R-spondin mRNA expression in primary human osteoblasts (hOB) by qPCR. As expected, these cells expressed high levels of the osteoblastic markers ALPL (alkaline phosphatase), BGLAP (osteocalcin), and COL1A1 (collagen 1A1) (Fig. S7A) . Interestingly, mRNA of all four R-spondins was readily detectable in primary hOB, with RSPO2 and RSPO3 showing the highest expression levels (Fig. 6A) . To extend these data and allow functional studies, we analyzed R-spondin expression in preosteoblast cell lines and in in vitro-differentiated osteoblasts, marked by high expression of the osteoblastic markers alkaline phosphatase (akp2) and osteocalcin (bglap) and high alkaline phosphatase (AP) activity (Fig. S7 B and C) . Rspo2 and rspo3 mRNA was readily detectable in both preosteoblasts and osteoblasts (Fig. S7D) . Surprisingly, R-spondin expression was markedly reduced in transition from preosteoblast to osteoblast. (Fig. S7D) . Functionally, (pre)osteoblast-conditioned media facilitated autocrine Wnt signaling in LME-1 and robustly synergized with exogenous Wnts in activating Wnt signaling in all cell lines tested ( Fig. 6B and Fig.  S7E ). However, by itself, and even if combined with exogenous R-spondins, (pre)osteoblast-conditioned media lack the capacity to activate Wnt signaling in OPM2 and XG-3 cells, indicating that functional Wnts are absent in (pre)osteoblast-conditioned media (Fig. 6B and Fig. S7E ). These results identify (pre)osteoblasts as a
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LGR4 potential source of R-spondin in the BM niche that may facilitate Wnt/β-catenin signaling in MM via aberrantly expressed LGR4.
Discussion
Wnt/β-catenin pathway activation in MM is associated with disease progression and drug resistance and mediates MM cell proliferation (5-9). Because classical Wnt-pathway-activating mutations have not been described in MM, aberrant Wnt activity was proposed to be driven by the BM microenvironment. This Wnt pathway activation may be further boosted by epigenetic loss of Wnt pathway inhibitors, including sFRPs and DKK1 (8, 41, 42) , as well as by mutational inactivation of CYLD, a gene encoding a deubiquiting enzyme that negatively regulates Wnt signaling in MM (43), all of which are common events in advanced MM. However, the exact mechanism(s) driving Wnt pathway activation in MM remains undefined. Our current study demonstrates that Wnt pathway activation in MM is facilitated by a proximal event in the Wnt pathway, i.e., by aberrant expression of LGR4. This enables MM cells to hijack R-spondins produced by (pre)osteoblasts in the MM niche, thereby deregulating Wnt (co)receptor turnover and causing hypersensitivity of MM cells to autocrine and paracrine Wnts (Fig. S8) . Interestingly, analysis of primary MM exome sequencing data from Lohr et al. (2) revealed that RNF43 and ZNRF3, the E3 ligases that are subject to inhibition by LGR/ R-spondin signaling, harbor mutations in primary MM at low frequency (together 4/203, 2%). Mutations in these genes have been shown to drive Wnt signaling in other tumors (17) (18) (19) ; however, the effect of these specific mutations on Wnt signaling in MM remains to be established. In addition, in analyzing the data of Mulligan et al. (44) involving targeted sequencing of established oncogenes, we identified a T41I mutation in β-catenin (CTNNB1) and a frameshift mutation in APC (S1465fs*3), both of which have been shown to drive oncogenic Wnt signaling (45, 46) . Thus, these mutations might represent alternative mechanisms driving Wnt signaling in a subset of MMs. The seminal finding of our study is that LGR4 is expressed by the majority of pMMs and HMCLs, whereas normal bone marrow plasma cells and B cells are completely devoid of LGR4. This designates aberrant LGR4 expression as a hallmark of malignancy and suggests that it can contribute to MM pathogenesis. Importantly, LGR4 expression is independent of the specific molecular MM subgroups, indicating that neither of the common MM subgroup-specific genomic alterations drives LGR4 expression. Rather, we found that STAT3 signaling, which is activated in the vast majority of MMs and is well known for its role in inflammation and cancer, mediates aberrant LGR4 expression (26) (27) (28) . This finding is of great interest because it links oncogenic Wnt activity in MM to inflammation and deregulated cytokine signaling. Although a wide variety of cytokines and growth factors are capable of activating STAT3, activation of STAT3 in MM typically results from auto-or paracrine IL-6 signaling (26, 28) . Indeed, we found that IL-6 stimulation leads to STAT3-mediated LGR4 up-regulation. Recently, Dechow et al. (27) reported that chronic STAT3 activation cooperates with MYC, which is a transcriptional target of β-catenin (16), in the development of MM. This underscores the importance of simultaneous activation of STAT3 signaling and Wnt/β-catenin signaling in MM pathogenesis.
Wnts are produced by BM stromal cells and play a role in the control of hematopoietic stem cell homeostasis and early B-cell development (36, 37) . Likewise, Wnt signaling in MM can be activated by paracrine Wnt ligands emanating from the BM niche, which is mimicked in vitro by stimulation with exogenous Wnts. In addition, gene-expression studies showed overexpression of Wnts in MM (6, 8) , suggesting autocrine signaling. Our functional studies show that R-spondin/LGR4 interaction strongly amplifies the response to exogeneous/paracrine Wnts. Moreover, the finding that R-spondin can also potentiate Wnt signaling in the absence of exogenously added Wnts, and that small-molecule inhibitors of Wnt secretion mitigate this effect, firmly establishes the existence of an autocrine Wnt-signaling loop in a subset of MMs. Downstream inhibition of Wnt signaling was previously shown to impair MM proliferation (5-7, 9, 35) . Interestingly, our current results indicate that a subset of HMCLs are also sensitive to proximal Wnt pathway inhibition by porcupine inhibitors and LGR4 silencing. MM cell lines are almost invariably derived from MM cells in a leukemic phase of the disease at which the malignant cells have lost their dependence upon the BM niche. By contrast, however, the vast majority of primary MMs is strictly dependent upon a protective BM niche for growth and survival. Therefore, primary MM will most likely be more vulnerable to inhibition of Wnts and/or R-spondins emanating from the BM niche. Whereas the presence of Wnt ligands in the BM niche is well established, expression of R-spondins in the BM microenvironment thus far has remained largely unexplored. Because autocrine R-spondins have been suggested to regulate differentiation of osteoblasts (38) , which are important constituents of the MM niche (39, 40) , we hypothesized that osteoblasts could be a major source of R-spondins driving oncogenic Wnt signaling. Corroborating this hypothesis, we found expression of several R-spondins in (pre)osteoblasts and demonstrated that (pre)osteoblast-conditioned media robustly synergized with Wnt ligands in activating Wnt signaling. Notably, we observed that R-spondin expression decreases during differentiation of preosteoblasts to osteoblasts. This suggests a scenario in which active suppression of osteoblast differentiation by MM cells (47) may lead to increased local levels of R-spondins, creating a feed-forward loop that drives Wnt signaling in the tumor cells.
In summary, we have uncovered a previously unknown role for the LGR4/R-spondin axis in regulating Wnt/β-catenin in MM cells. Importantly, we demonstrate that the R-spondin effects are fully dependent on LGR4, implying that, unlike in intestinal epithelium where LGR4 and LGR5 have redundant functions, therapeutic targeting of LGR4 in MM will be sufficient to abolish R-spondin-mediated Wnt signaling amplification. These findings identify LGR4/R-spondin signaling as a therapeutic target for MM patients.
Materials and Methods
For additional information on methods, see SI Materials and Methods.
Plasmids and Cloning. pTRIPZ-shLGR4 and pTRIPZ-shSTAT3 were constructed as previously described (48) . In short, a 97-mer template was amplified by PCR and inserted in the XhoI/EcoRI site of the pTRIPZ vector (Thermo Scientific). Targeting sequences were GCGTAATCAAATCTACCAAAT (hLGR4) and GCA-CAATCTACGAAGAATCAA (hSTAT3). pLentiCrispr-sgLGR4 was constructed by inserting sgLGR4 (GCAGCTGCGACGGCGACCGT, chr11:27493733-27493752, hg19) in pLentiCrispr (Addgene) as previously described (49) . TOP-GFP. mCh/FOP-GFP.mCh (Addgene 35491 and 35492) were kind gifts from David Horst, Ludwig-Maximilians-Universität München (LMU), Munich (50) . pEF. STAT3DN.Ubc.GFP (24984), pEF.STAT3C.Ubc.GFP (24983), and EdTC (dnTCF4, 24310) were obtained from Addgene.
Microarray Data Analysis. Datasets presented in Fig. 1 and Fig. S1 A and B were obtained from the publically available Amazonia! web atlas (51) Error bars indicate ± SEM of three independent transductions. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 using unpaired Student's t-test. (B) Flow cytometry analysis of the effect of the small-molecule Wnt inhibitors IWP-2 and LGK974 on HMCL expansion after 4 d of culture, relative to day 0. Error bars indicate ± SEM of three independent transductions. *P ≤ 0.05 using unpaired Student's t-test. (C) Flow cytometry analysis of the effect of doxycycline-induced shRNAmediated silencing of LGR4 on MM cell expansion at day 4 of culture, relative to day 0. Error bars indicate ± SEM of three independent experiments in triplicate. *P ≤ 0.05 and **P ≤ 0.01 using unpaired Student's t-test. Analysis of Wnt activity in TOP-GFP-transduced LME-1 cells treated with R-spondin 2 or low levels of Wnt3a (25 ng/mL) in the absence (white) or presence (black) of osteoblast-conditioned medium (KS483). Error bars indicate ± SEM of three independent experiments in triplicate; *P ≤ 0.05 and ***P ≤ 0.001 using one-way ANOVA with Bonferroni correction.
(Winter et al. GSE14615), diffuse large B-cell lymphoma (n = 51) (58), follicular lymphoma (n = 20) (59) , chronic lymphoid leukemia (n = 124) (54, (60) (61) (62) , multiple myeloma (n = 30), and intestinal tissues (n = 8) (Roth et al. GSE7307). The microarray dataset presented in Fig. S1 C and D contained gene-expression data of primary MM samples divided into subgroups based on molecular profiling that was normalized as described (25) . Molecular subgroups were previously identified and include the CD1 (n = 18), CD2 (n = 26), hyperdyploid (n = 47), low bone disease (n = 23), MAF/MAFB (n = 13), MMSET (n = 36), myeloid gene signature (n = 71), and proliferation (n = 21) subgroups.
